Toll-Like Receptor 4 Composite Genotype

Your immune system has a built-in bacterial alarm. TLR4 is short for toll-like receptor 4. It is one of the sensors that helps your body notice gram-negative bacteria and start inflammation. Small differences in the TLR4 gene are wired into you from birth. Some variants can quiet the signal. That may mean less inflammation in some settings, but weaker sensing of certain bacterial threats in others. Other variants have been linked to a louder inflammatory response.

This test reads several inherited TLR4 variants at once from a saliva sample. The result does not change over your lifetime. It tells you which version of the sensor you were born with, and where that version has been linked to higher or lower risk for specific conditions.

What This Test Reads

TLR4 sits on immune cells and on cells that line the gums, gut, and airways. When it senses LPS from gram-negative bacteria, it starts a signal that recruits IL-6, TNF-alpha, and other cytokines. Cytokines are inflammatory messenger proteins. That response is how your body knows to fight back.

A composite genotype reads several common single-letter changes in TLR4 together. Asp299Gly (rs4986790) is the best-studied. It changes the receptor's outer domain and can blunt the response to LPS by disrupting how the receptor recruits its signaling partners MyD88 and TRIF, rather than by changing how much TLR4 a cell makes. Thr399Ile (rs4986791) often travels with Asp299Gly in Europeans, but its independent effect is unclear. Other reported sites, including rs1927914, rs1927911, rs2149356, rs2737190, rs2737191, and rs10759932, are gene-control or noncoding variants. They may shift how much TLR4 a cell makes or how strongly the pathway responds. Reading them together gives a broader genetic read, but it has not been validated as a single clinical risk score.

A saliva or buccal swab gives the same inherited DNA a blood draw would. The genotype is the same whether it comes from your cheek, blood, or gum tissue, unless a rare situation such as a bone marrow transplant changes which cells are being sampled.

Gum Disease and Oral Infection

Periodontitis is one of the most studied contexts for TLR4 variants, but the evidence is genuinely mixed. In a Finnish cohort of 223 adults, the Asp299Gly signal showed up only when P. gingivalis was present: carriers with the bacterium had more bone loss around their teeth, while the same variant without the bacterium was not the problem. A separate 616-subject U.S. cohort found the opposite direction, with Asp299Gly appearing protective against alveolar bone loss in P. gingivalis carriers. Broader meta-analyses have not found a consistent overall association.

In 241 Chinese adults, rs1927911, rs2149356, and rs2737190 were tied to higher odds of moderate-to-severe chronic periodontitis in people already infected with P. gingivalis. Asp299Gly and Thr399Ile were absent in that cohort. That matters: TLR4 variant frequencies swing hard by ancestry.

The useful read is simple. A TLR4 result matters most in combination with what is actually growing in your mouth. A carrier who keeps a low-pathogen oral microbiome may never see a consequence.

Gout and Uric Acid Inflammation

TLR4 also helps immune cells respond to danger signals from inside the body, including uric acid crystals that drive gout attacks. Two Chinese case-control studies point to this pathway. In 1,128 people, rs2149356 TT was linked to about 1.9-fold higher gout risk and higher TLR4 gene activity plus IL-1 beta during acute gout. In 1,207 Han Chinese men, rs2737191 AG was linked to higher gout risk and higher serum TLR4 protein. Replication is uneven. The rs2149356 signal has appeared in European samples, gone in the opposite direction in Polynesians, and failed to show up in some incident-gout cohorts. Asp299Gly and Thr399Ile were absent in Chinese Han gout patients. If you carry one of these variants and uric acid runs high, the setup for more inflammatory flares is more plausible. It is still association data, not a diagnosis.

Infection Defense

Some reduced-signaling variants that quiet inflammation can weaken pathogen sensing. In critically ill surgical patients, one study reported that 79% of TLR4 Asp299Gly or Thr399Ile carriers developed gram-negative infections (11 of 14 carriers), compared with 17% of people with the standard sequence (11 of 63). A 2026 ethnogeographic meta-analysis of 29 studies and about 9,196 participants supported this direction, with Asp299Gly linked to roughly double the odds of gram-negative infection and higher infection-related mortality. A 2024 sepsis-specific meta-analysis did not show a clear sepsis-risk increase; if anything, Asp299Gly trended weakly protective. So TLR4 genotype is not a general sepsis predictor. It is a context clue when gram-negative bacterial sensing matters.

During the COVID-19 pandemic, a German cohort of 1,570 people found that the Asp299Gly variant roughly halved the odds of hospitalization, ICU admission, or death from COVID-19. Other COVID genetic studies have pointed the other way: rs4986791 has been linked to worse outcomes in some cohorts, and the GG genotype at rs4986790 has been associated with severe disease and ARDS in a Mexican cohort. Any one COVID result should not guide care by itself.

Heart, Metabolic, and Other Links

The Bruneck Study, which followed 810 community-dwelling adults, found that Asp299Gly carriers had about half the risk of carotid atherosclerosis (odds ratio 0.54, 95% CI 0.32 to 0.98) and lower IL-6 and fibrinogen than non-carriers, while severe bacterial infections were more common. This finding has not consistently replicated. A larger 3,000-person CAPS cohort found no TLR4 association with carotid intima-media thickness, and a Stockholm cohort found the hyporesponsive allele more common among heart attack survivors. TLR4 variants have also been linked to type 2 diabetes risk, though findings vary by population. In MASLD, Asp299Gly and Thr399Ile variant genotypes were associated with roughly 3.5-fold and 9.9-fold higher odds of MASH in a small exploratory study. In rheumatoid arthritis in a Chinese Han population, two TLR4 variants roughly doubled to tripled susceptibility. In inflammatory bowel disease, meta-analysis links Asp299Gly to Crohn's in Caucasians but not Asians. These are association findings from often small or single-population studies, not proven causes, and effect sizes vary a lot by population.

Reading a Trade-Off, Not a Verdict

TLR4 does not fit a clean "good number" or "bad number" frame. The same reduced-function variants that appear protective against atherosclerosis and severe COVID-19 in some cohorts also appear to raise vulnerability to certain gram-negative bacterial infections. This is an immune wiring clue, not a scorecard. What matters is the pairing: which variants you carry, and which exposures you meet. A person with reduced-function TLR4 who avoids poorly controlled gram-negative infections is in a different situation than a person with the same genotype in an ICU.

How Common the Variants Are

In the Finnish periodontitis cohort, 87.4% of adults carried two copies of the standard sequence at Asp299Gly and 12.6% were heterozygous. In the Chinese cohort, Asp299Gly and Thr399Ile were absent. Ancestry drives variant frequency, and it drives which variants a saliva panel will meaningfully report. If you get a negative result for a variant that is rarely seen in your ancestry, it does not rule out other TLR4 biology.

A One-Time Test That Guides Ongoing Choices

You do not retest a germline genotype. The value is in what you do with it over years. If you carry a higher-signaling TLR4 variant, the interventions that matter are the ones that reduce your inflammatory exposures: dental hygiene and periodontal maintenance if you have oral pathogens, uric acid control if you are prone to gout, and closer attention to markers like hs-CRP, IL-6, and oral pathogen screening. If you carry a reduced-function variant, awareness matters most when a real bacterial threat comes into play, such as ICU admission, chemotherapy, or signs of a serious infection.

What To Do With an Unexpected Result

A high-signaling result does not diagnose anything. Pair it with tests that show what is happening in your body right now: an oral pathogen panel if you want to know whether P. gingivalis is present, hs-CRP for systemic inflammation, uric acid if you have joint pain, and a lipid and metabolic workup if you are asking about cardiovascular or diabetes risk. A reduced-function result is a reason to seek care earlier if signs of a serious bacterial infection appear. Bring the specific variants to your clinician when infection risk, immune disease, or prescription decisions are on the table. A genetic counselor is reasonable for unusual family patterns, but rarely needed for a common-variant panel.

What This Test Cannot Tell You

TLR4 genotype is not a diagnosis of periodontitis, gout, sepsis risk, or heart disease. Association studies from single populations often fail to replicate in others, and the effect sizes for most conditions are modest. A negative result only rules out the sites the lab reads. It does not rule out rare TLR4 variants or other immune genes. If whole-genome sequencing reports a TLR4 change the lab cannot interpret, do not treat it as risk or protection. No professional society recommends TLR4 screening in asymptomatic adults, and no trial has shown that knowing your genotype changes outcomes. The evidence is strong enough to inform decisions when paired with other data, but not strong enough to drive treatment alone.